Chip stocks fall with Nvidia after data center rev disappointment
Repare Therapeutics Inc. (RPTX) stock has tumbled to a 52-week low, touching down at $1.05. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 6.77 and holds more cash than debt on its balance sheet. This significant drop reflects a challenging year for the company, with the stock price plummeting by -76.6% from the previous year. Investors have been closely monitoring Repare Therapeutics as it navigates through a period marked by volatility and downward pressure, raising concerns about the company’s future prospects and the broader biotechnology sector’s performance. The 52-week low serves as a critical juncture for Repare Therapeutics, as market participants consider the stock’s valuation and the potential for a rebound. Despite current challenges, analysts maintain price targets ranging from $3 to $8, suggesting potential upside. Get access to 10+ additional exclusive insights and detailed financial metrics with InvestingPro.
In other recent news, Repare Therapeutics reported a diluted net loss of $2.00 per share for 2024, aligning with H.C. Wainwright’s forecast. The company’s R&D and SG&A expenses were slightly lower than expected, and H.C. Wainwright projects a reduced net loss of $2.11 per share for 2025. Repare holds $152.8 million in cash, expected to support operations until late 2027. Despite this, H.C. Wainwright lowered its price target for Repare to $5.00, maintaining a Buy rating. Stifel also adjusted its price target to $3.00 but kept a Buy rating, noting Repare’s strategic shift to early-stage assets. Meanwhile, Bloom Burton downgraded Repare to Hold, citing the absence of human data for its early-stage drugs. Repare’s ongoing clinical trials, including the POLAR and LIONS trials, anticipate key results by late 2025. The company has reduced its workforce by 75% to extend its financial runway amidst these developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.